ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025)

ArriVent BioPharma (AVBP) posted Long-Term Investments of $5.1 million for Q3 2025, down 72.82% sequentially from $18.8 million in Q2 2025.

ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025) Analysis & Trends

ArriVent BioPharma has reported Long-Term Investments for 2 years, with the latest figure at $5.1 million in Q3 2025.

Quarterly Long-Term Investments changed N/A year-over-year to $5.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $5.1 million (changed N/A YoY) and the FY2024 annual result came in at $47.7 million, changed N/A from the prior year.
Long-Term Investments declined to $5.1 million in Q3 2025 per AVBP's latest filing, from $18.8 million in the prior quarter.
Over five years, Long-Term Investments peaked at $47.7 million in Q4 2024 and troughed at $5.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	372.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.17 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	ArriVent BioPharma	1.43 Bn	1.43 Bn	-	-

Download Data